173
Participants
Start Date
March 15, 2013
Primary Completion Date
March 3, 2017
Study Completion Date
November 7, 2017
Inotersen
Placebo
Mount Sinai Medical Center, New York
Columbia University Medical Center - The Neurological Institute, New York
Penn Presbyterian Medical Center, Philadelphia
Johns Hopkins University Bayview Medical Center, Baltimore
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo, Pavia
Indiana University School of Medicine, Indianapolis
UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin, Münster
Mayo Clinic, Rochester
University of California, Irvine, Orange
CHU Henri Mondor - Department of Neurology, Créteil
CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network, Le Kremlin-Bicêtre
Oregon Health & Science University, Portland
"Universita Degli Studi Di Messina - Azienda Ospedaliera Universitaria Policlinico Gaetano Martino", Messina
Boston University School of Medicine - Amyloid Treatment & Research Program, Boston
FLENI, Buenos Aires
AACD, São Paulo
UNIFESP, São Paulo
Auckland City Hospital, Auckland
Federal University of Rio de Janeiro - University Hospital, Rio de Janeiro
CHLN - Hospital de Santa Maria, Lisbon
CHP-HGSA, Unidade Clinica de Paramiloidose, Porto
Hospital Universitari Vall D' Hebron, Barcelona
Hospital Clínic, Barcelona
University College London - National Amyloidosis Centre, London
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY